Free Trial
NASDAQ:SLNO

Soleno Therapeutics Q1 2025 Earnings Report

Soleno Therapeutics logo
$73.26 -0.97 (-1.31%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$73.28 +0.02 (+0.03%)
As of 04/25/2025 04:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Soleno Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$1.08
Beat/Miss
N/A
One Year Ago EPS
N/A

Soleno Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Soleno Therapeutics Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
Wednesday, May 7, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Soleno Therapeutics Earnings Headlines

Soleno Therapeutics price target raised to $145 from $93 at Piper Sandler
Piper Sandler Sticks to Its Buy Rating for Soleno Therapeutics (SLNO)
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.
Soleno Therapeutics announces VYKAT XR launch
See More Soleno Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Soleno Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Soleno Therapeutics and other key companies, straight to your email.

About Soleno Therapeutics

Soleno Therapeutics (NASDAQ:SLNO), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

View Soleno Therapeutics Profile

More Earnings Resources from MarketBeat